Cargando…

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

BACKGROUND: Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expressing programmed death ligand 1 (PD-L1). METHODS: Patients with advanced thyroi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehnert, Janice M., Varga, Andrea, Brose, Marcia S., Aggarwal, Rahul R., Lin, Chia-Chi, Prawira, Amy, de Braud, Filippo, Tamura, Kenji, Doi, Toshihiko, Piha-Paul, Sarina A., Gilbert, Jill, Saraf, Sanatan, Thanigaimani, Pradeep, Cheng, Jonathan D., Keam, Bhumsuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399859/ https://www.ncbi.nlm.nih.gov/pubmed/30832606 http://dx.doi.org/10.1186/s12885-019-5380-3

Ejemplares similares

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
por: Cohen, Roger B., et al.
Publicado: (2018)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
por: O’Neil, Bert H., et al.
Publicado: (2017)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
por: Ott, P. A., et al.
Publicado: (2017)

PD‐L1 and PD‐1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor
por: Pakkanen, Emma, et al.
Publicado: (2022)

HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor
por: Chang, Hyeyeon, et al.
Publicado: (2020)

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
por: Wang, Simiao, et al.
Publicado: (2023)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Pembrolizumab Induces an Unexpected Conformational Change in the CC′-loop of PD-1
por: Roither, Bernhard, et al.
Publicado: (2020)

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
por: Oh, So Yeon, et al.
Publicado: (2021)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
por: Giraldo, Nicolas A., et al.
Publicado: (2018)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

PD-1 Controls Follicular T Helper Cell Positioning and Function
por: Shi, Jingwen, et al.
Publicado: (2018)

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
por: Bai, Yanhua, et al.
Publicado: (2017)

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
por: Na, Zhenkun, et al.
Publicado: (2017)

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
por: Horita, Shoichiro, et al.
Publicado: (2016)

Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry
por: Tavares, Ana Beatriz M. L. A., et al.
Publicado: (2018)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

SAT-242 Isolated Adrenocorticotropic Hormone Deficiency Secondary to the PD-1 Inhibitor Pembrolizumab
por: Mathew, Justin, et al.
Publicado: (2020)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
por: Gorshein, Elan, et al.
Publicado: (2021)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

PD-L1 expression in papillary renal cell carcinoma
por: Motoshima, Takanobu, et al.
Publicado: (2017)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
por: Bialek, Joanna, et al.
Publicado: (2022)

Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report
por: Li, Sicheng, et al.
Publicado: (2018)

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
por: Isshiki, Takuma, et al.
Publicado: (2018)

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
por: Fessas, Petros, et al.
Publicado: (2017)

Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report
por: Misir Krpan, Ana, et al.
Publicado: (2020)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
por: Lin, Shen, et al.
Publicado: (2022)

Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report
por: Goldstein, Jennifer, et al.
Publicado: (2015)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
por: Lee, Eun-Ji, et al.
Publicado: (2021)

Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012
por: Tahara, Makoto, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i78csil8navl2ker4kg46aegmk